Company: ISRG
Filing Date: 2025-01-31
Form Type: 10-K
Source: 0001035267-25-000017
Chunk: 162

Company: INTUITIVE SURGICAL INC
Filing Date: 2025-01-31
Form: 10-K
Item: Item 8
Chunk 162
---
es lessthan 12 monthsUnrealized losses 12months or greaterTotalDecember 31, 2024FairValueUnrealizedLossesFairValueUnrealizedLossesFairValueUnrealizedLossesU.S. treasuries $2,744.4 $(23.3)$190.1 $(4.2)$2,934.5 $(27.5)Corporate debt securities— — 218.7 (3.7)218.7 (3.7)U.S. government agencies178.1 (1.2)106.7 (1.2)284.8 (2.4)Municipal securities— — 4.6 (0.1)4.6 (0.1)Total$2,922.5 $(24.5)$520.1 $(9.2)$3,442.6 $(33.7)December 31, 2023      U.S. treasuries$48.5 $— $1,112.9 $(25.4)$1,161.4 $(25.4)Corporate debt securities54.2 (0.1)1,219.2 (25.8)1,273.4 (25.9)U.S. government agencies29.8 — 185.6 (7.3)215.4 (7.3)Municipal securities— — 77.4 (1.9)77.4 (1.9)Total$132.5 $(0.1)$2,595.1 $(60.4)$2,727.6 $(60.5)The current unrealized losses on the Company’s available-for-sale debt securities were caused by interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than the amortized cost basis of the investments. As of December 31, 2024, the Company does not intend to sell the investments in unrealized loss positions, and it is not more-likely-than-not that the Company will be required to sell any of the investments before recovery of their amortized cost basis, which may be at maturity. Therefore, the Company does not expect to realize any losses on these available-for-sale debt securities. Additional factors considered in determining the treatment of unrealized losses include the